Although triple treatment did not further reduce CD133+ surface population compared to dual treatments, it reduced SOX2 expression a widely used marker for repopulating cells in context of radiation resistance [41–42] as well as Nestin another stem cell marker in glioma progression [43–44]. The gene discussed is PROM1; the disease is glioma.